SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MorphoSys AG (MOR)
An SI Board Since January 2000
Posts SubjectMarks Bans
421 15 0
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
296MorphoSys AG Reports Positive Results for Fiscal Year 2009 02/25/2010 at 07:00 AGermanecki-3/2/2010
295AbD Serotec Significantly Improves Antibody Generation Process 02/23/2010 at 07Germanecki-2/23/2010
294MorphoSys and Galapagos Expand Antibody Alliance 02/18/2010 at 07:30 AM MorphoGermanecki-2/18/2010
293Directors’ Dealings Declared security transactions Date Name and Function TranGermanecki-1/28/2010
292MorphoSys Licenses HuCAL PLATINUM® Antibody Library to Shionogi in ResearchGermanecki-1/28/2010
291MorphoSys and WACKER Expand Cooperation to Use WACKER's ESETEC® TechnolGermanecki-1/20/2010
290MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 ProgramGermanecki-1/19/2010
289MorphoSys Chief Uses Crisis to Scout for Takeovers, FTD Says By Angela Cullen Germanecki-12/25/2009
288MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MGermanecki-11/9/2009
287MorphoSys AG Reports Results for the First Nine Months of 2009 10/28/2009 at 07:Germanecki-10/28/2009
286MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies Germanecki-10/20/2009
285Roche plans to start P2-Study in Alzheimer desease efkabe.de RG1450 is a fullyGermanecki-10/15/2009
284Phase 2 Study in Patients With Metastatic Prostate Cancer started A Study of thGermanecki-10/13/2009
283German biotechnology company MorphoSys has appointed Lisa Rojkjaer as its new viGermanecki-9/17/2009
282MorphoSys AG's AbD Serotec and FIND Sign Agreement to Develop Temperature StGermanecki-9/14/2009
281MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering PhaGermanecki-9/8/2009
280R&D Manager Dr. Schottelius is buying shares! hugingroup.com MorphoSys AG Germanecki-9/3/2009
279Presentation from European Healthcare Investors Conference Sal. Oppenheim AugustGermanecki-9/3/2009
278MorphoSys to Present at Six Upcoming Investor Conferences MARTINSRIED / MÜNGermanecki-8/28/2009
277MorphoSys AG Reports Six Months 2009 Results 07/29/2009 at 07:00 AM Pipeline EGermanecki-7/29/2009
276First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTGermanecki-7/14/2009
275Massachusetts Mutual Life Insurance Company has exceeded the threshold of 5% of Germanecki-7/10/2009
274AbD Serotec and Spinreact Sign Supply Agreement for Antibodies Used in Clinical Germanecki-7/9/2009
273MorphoSys Secures Full-Term of Strategic Alliance 07/06/2009 at 07:30 AM MorpGermanecki-7/6/2009
272MorphoSys and the University of Melbourne File New Patent Applications in MOR103Germanecki-7/6/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News